NCT06215716: An ongoing trial by Akero Therapeutics, Inc
This trial is ongoing. It must report results 7 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06215716 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 1, 2023 |
| Completion date | Nov. 30, 2032 |
| Required reporting date | Nov. 30, 2033, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |